Holen Sie sich die Stockscreener-App
12.93
7.64%
-1.07
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Ellsworth Advisors LLC Buys New Stake in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Form 8K Cullinan Therapeutics, Inc For: 2 October By Investing.com - Investing.com South Africa
Up to $100M hinges on first-line approval as Cullinan (CGEM) starts a lung cancer drug submission. - Stock Titan
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Has Consensus Price Target of $33.71 According to Analysts - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance UK
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program - GlobeNewswire Inc.
Cullinan Therapeutics (NASDAQ:CGEM) Given "Buy" Rating at BTIG Research - MarketBeat
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases - Seeking Alpha
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance Australia
510,325 Shares in Cullinan Therapeutics, Inc. $CGEM Purchased by Bank of America Corp DE - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 7.1%Here's What Happened - MarketBeat
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - GlobeNewswire Inc.
Cullinan Therapeutics (NasdaqGS:CGEM) Stock Price - Simply Wall Street
Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Potential Upside of Over 57% Ignites Investor Interest - DirectorsTalk Interviews
Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen - MarketBeat
EGFR-NSCLC Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innova - Barchart.com
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - Investing News Network
Cullinan Therapeutics to Present Phase 3 REZILIENT3 Interim Data on Zipalertinib Plus Chemotherapy at WCLC 2026, Host Investor Event - Quiver Quantitative
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - The Manila Times
Cullinan Therapeutics to Host Virtual Analyst and Investor - GlobeNewswire
Cullinan Therapeutics CSO Jennifer Michaelson Executes 8,000 Share Sale Under 10b5-1 Plan - Kalkine Media
Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics (CGEM) insider sells 8,000 shares under pre-arranged plan - Stock Titan
171,031 Shares in Cullinan Therapeutics, Inc. $CGEM Bought by Bank of New York Mellon Corp - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Corient Private Wealth LP Takes $970,000 Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
The Manufacturers Life Insurance Company Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
CGEM Should I Buy - Intellectia AI
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded to Hold at Wall Street Zen - MarketBeat
Moore Capital Management LP Raises Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Algert Global LLC Sells 72,880 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
BlackRock Inc. Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - marketbeat.com
Connor Clark & Lunn Investment Management Ltd. Takes Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Elmind Capital LP Purchases New Shares in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Boone Capital Management LLC Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics shows strong multi-asset pipeline with key drug milestones boosting funding prospects. - Pluang
Bank of America Corp DE Acquires 170,417 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Deutsche Bank AG Purchases Shares of 382,840 Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Cullinan (CGEM) Quarterly Figures: Reported EPS Tops Expectations at the Close; After Results: The Share Price Adds 0.65% in the Latest SessionEarnings Yield Analysis - vinanet.vn
Cullinan (CGEM) Quarterly Figures: Reported EPS Tops Expectations at the Close; After Results: The Share Price Adds 0.65% in the Latest SessionCapex Guidance - vinanet.vn
Blue Owl Capital Holdings LP Invests $28.04 Million in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Tokyo’s Taiho and Cullinan Announce Positive Phase 3 Lung Cancer Results - geneonline.com
Is Cullinan Therapeutics (CGEM) Fully Valued After Its Phase 3 Trial Win? - simplywall.st
Taiho, Cullinan trial results selected for lung cancer conference By Investing.com - Investing.com Australia
Cullinan Therapeutics (CGEM) to Present Phase 3 REZILIENT3 Trial - GuruFocus
Taiho, Cullinan trial results selected for lung cancer conference - Investing.com
Taiho, Cullinan trial results selected for lung cancer conference By Investing.com - Investing.com India
Taiho, Cullinan trial results selected for lung cancer conference By Investing.com - Investing.com UK
3.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):